India's pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23. India's pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23.India's
The Subject Expert Committee (SEC) under the Central Drugs Control Standard Organisation on Friday recommended Serum Institute of India's (SII) Covid-19 vaccine, Covovax, for emergency use authorisation in the 12-17 age group, people in the know told
The pharmacovigilance market is anticipated to register a CAGR of 10.5 percent until 2030. The rise in the incidence of ADRs is a major factor fuelling the market growth.
CARE Ratings expects India's pharma segment to develop at an annual rate of roughly 11% over the next two years, reaching a value of more than $60 billion.
Medicine retailers and distributors in Delhi have urged the state government to issue an order restraining online and offline pharmacies from offering discounts.Medicine retailers and distributors in Delhi have urged the state government to issue an
Brinton, the Indian Pharmaceutical Multinational, which has been steadily increasing its footprint in the Indian and global healthcare sector, in a strategic move today announced a tie-up with the global foot care brand, Scholl Wellness Company, for
Mankind Pharma on Monday said it will acquire Panacea Biotec Pharma's formulations brands, for India and Nepal markets, for Rs 1,872 crore
The Covid-19 pandemic has not led a huge demand for innovations in the pharma sector, but has also given a fillip to research and development (R&D), which have become the most important segment needed to meet the rising demand of more vaccines, along
Biocon Biologics Ltd (BBL) the subsidiary of Biocon on Monday said it has entered into a definitive agreement to acquire Viatris’ biosimilars assets for $3.34 billion. Biocon Biologics Ltd (BBL) the subsidiary of Biocon on Monday said it has entered.
With the increasing geo-political tensions between Russia and Ukraine, the Indian pharmaceutical segment is expected to witness a tremor in its operations.
, CDSCO.jpg)
